Lipid-dependent regulation of neurotransmitter release from sympathetic nerve endings in mice atria

Biochim Biophys Acta Biomembr. 2023 Oct;1865(7):184197. doi: 10.1016/j.bbamem.2023.184197. Epub 2023 Jul 1.

Abstract

Neurotransmitter release from sympathetic terminals is a key avenue for heart regulation. Herein, presynaptic exocytotic activity was monitored in mice atrial tissue using a false fluorescent neurotransmitter FFN511, a substrate for monoamine transporters. FFN511 labeling had similarity with tyrosine hydroxylase immunostaining. High [K+]o depolarization caused FFN511 release, which was augmented by reserpine, an inhibitor of neurotransmitter uptake. However, reserpine lost the ability to increase depolarization-induced FFN511 unloading after depletion of ready releasable pool with hyperosmotic sucrose. Cholesterol oxidase and sphingomyelinase modified atrial membranes, changing in opposite manner fluorescence of lipid ordering-sensitive probe. Plasmalemmal cholesterol oxidation increased FFN511 release upon K+-depolarization and more markedly potentiated FFN511 unloading in the presence of reserpine. Hydrolysis of plasmalemmal sphingomyelin profoundly enhanced the rate of FFN511 loss due to K+-depolarization, but completely prevented potentiating action of reserpine on FFN511 unloading. If cholesterol oxidase or sphingomyelinase got access to membranes of recycling synaptic vesicles, then the enzyme effects were suppressed. Hence, a fast neurotransmitter reuptake dependent on exocytosis of vesicles from ready releasable pool occurs during presynaptic activity. This reuptake can be enhanced or inhibited by plasmalemmal cholesterol oxidation or sphingomyelin hydrolysis, respectively. These modifications of plasmalemmal (but not vesicular) lipids increase the evoked neurotransmitter release.

Keywords: Cardiac sympathetic nerve terminals; Cholesterol, Sphingomyelin, Sphingomyelinase; Neurotransmitter release; Norepinephrine; Synaptic vesicle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrial Fibrillation*
  • Cholesterol / pharmacology
  • Cholesterol Oxidase / pharmacology
  • Mice
  • Nerve Endings
  • Neurotransmitter Agents / pharmacology
  • Reserpine* / pharmacology
  • Sphingomyelin Phosphodiesterase
  • Sphingomyelins / pharmacology

Substances

  • 8-(2-amino-ethyl)-2,3,5,6-tetrahydro-1H,4H-11-oxa-3a-aza-benzo(de)anthracen-10-one
  • Reserpine
  • Sphingomyelin Phosphodiesterase
  • Cholesterol Oxidase
  • Sphingomyelins
  • Neurotransmitter Agents
  • Cholesterol